Related Experiment Video

Updated: Mar 15, 2026

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

795

Effect of Linagliptin on Structural Changes in the Kidney in Experimental Type 2 Diabetes Mellitus

Yu S Gavrilova1, N P Bgatova2, V V Klimontov2

  • 1Research Institute of Clinical and Experimental Lymphology, Novosibirsk, Russia. inabrite@yandex.ru.

Bulletin of Experimental Biology and Medicine
|September 5, 2016
PubMed

Insights

Linagliptin, a dipeptidyl peptidase-4 inhibitor, protected kidney structure in a mouse model of type 2 diabetes. This protective effect on diabetic nephropathy was independent of blood sugar control.

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetic nephropathy is a major complication of type 2 diabetes mellitus.
  • Current treatments for diabetic nephropathy have limitations.
  • Dipeptidyl peptidase-4 (DPP-4) inhibitors are used to manage type 2 diabetes.

Purpose of the Study:

  • To investigate the effect of linagliptin on structural changes in diabetic nephropathy.
  • To determine if linagliptin's protective effects on the kidney are linked to its glucose-lowering action.

Main Methods:

  • A study was conducted using BKS.Cg-Dock7m+/+Leprdb/J mice, an established model for type 2 diabetes.
  • Mice received either linagliptin (10 mg/kg daily) or a vehicle control via gavage for 8 weeks.
  • Kidney tissue was examined for structural markers of nephropathy, including mesangial expansion and basement membrane thickening.

Main Results:

  • Linagliptin treatment significantly reduced mesangial expansion in the glomeruli.
  • Thickening of the glomerular capillary and proximal tubule basement membranes was less pronounced in linagliptin-treated mice.
  • Retraction of cytopodia, another indicator of kidney damage, was also reduced by linagliptin.
  • These structural improvements were observed without a significant decrease in blood glucose levels.

Conclusions:

  • Linagliptin demonstrates a protective effect on kidney structure in a mouse model of type 2 diabetes.
  • The renoprotective effects of linagliptin in this model are not mediated by its hypoglycemic activity.
  • These findings suggest a potential direct role for linagliptin in mitigating diabetic nephropathy beyond glucose control.
Keywords:
diabetic nephropathylinagliptintype 2 diabetes mellitus

More Related Videos

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

1.0K
Assessment of Kidney Function in Mouse Models of Glomerular Disease09:16

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Published on: June 30, 2018

18.8K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
876
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
821
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.2K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
813
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.3K
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.7K